NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Oblenio Bio

Oblenio Bio

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.obleniobio.com/

Last Round

Series B

Jun 25, 2026

Total Funding Raised

$62M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Oblenio Bio is a biotechnology company developing LBL-051, a tri-specific T-cell engager antibody, for the treatment of autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

tri-specific antibodyT-cell engagerautoimmune disease therapyB-cell depletionimmunotherapyimmune resetantibody therapydrug developmentCD19 targetBCMA targetbiologicspre-clinical biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Oblenio Bio Comps

Public and private peers based on sector, stage, and business model.

Oblenio Bio comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Oblenio Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJun 25, 2026
Series ANov 7, 2024

Key People

Founding team and executive leadership

Samantha Truex

CEO-in-Residence, CEO Of Oblenio Bio

Executive Team

Oblenio Bio Investors

Notable investors and investment history

Oblenio Bio investors
InvestorRounds
Aditum BioSeries B, Series A
GVSeries B
Deep Track CapitalSeries B
Pfizer VenturesSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 25, 2026

    $62M round led by Pfizer Ventures.

  • Nov 7, 2024

    Led by Aditum Bio with participation from Nanjing Leads Biolabs.

Oblenio Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Oblenio Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Oblenio Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range5
Year Founded2024
Last FundingJun 25, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.